225 related articles for article (PubMed ID: 12421831)
1. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition.
Okamoto K; Eger BT; Nishino T; Kondo S; Pai EF; Nishino T
J Biol Chem; 2003 Jan; 278(3):1848-55. PubMed ID: 12421831
[TBL] [Abstract][Full Text] [Related]
2. Y-700 [1-[3-Cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic acid]: a potent xanthine oxidoreductase inhibitor with hepatic excretion.
Fukunari A; Okamoto K; Nishino T; Eger BT; Pai EF; Kamezawa M; Yamada I; Kato N
J Pharmacol Exp Ther; 2004 Nov; 311(2):519-28. PubMed ID: 15190124
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of inhibition of xanthine oxidoreductase by allopurinol: crystal structure of reduced bovine milk xanthine oxidoreductase bound with oxipurinol.
Okamoto K; Eger BT; Nishino T; Pai EF; Nishino T
Nucleosides Nucleotides Nucleic Acids; 2008 Jun; 27(6):888-93. PubMed ID: 18600558
[TBL] [Abstract][Full Text] [Related]
4. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.
Takano Y; Hase-Aoki K; Horiuchi H; Zhao L; Kasahara Y; Kondo S; Becker MA
Life Sci; 2005 Mar; 76(16):1835-47. PubMed ID: 15698861
[TBL] [Abstract][Full Text] [Related]
5. Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051.
Okamoto K; Nishino T
J Nippon Med Sch; 2008 Feb; 75(1):2-3. PubMed ID: 18360072
[TBL] [Abstract][Full Text] [Related]
6. Different inhibitory potency of febuxostat towards mammalian and bacterial xanthine oxidoreductases: insight from molecular dynamics.
Kikuchi H; Fujisaki H; Furuta T; Okamoto K; Leimkühler S; Nishino T
Sci Rep; 2012; 2():331. PubMed ID: 22448318
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of Substrate and Inhibitor Binding of Rhodobacter capsulatus Xanthine Dehydrogenase.
Dietzel U; Kuper J; Doebbler JA; Schulte A; Truglio JJ; Leimkühler S; Kisker C
J Biol Chem; 2009 Mar; 284(13):8768-76. PubMed ID: 19109249
[TBL] [Abstract][Full Text] [Related]
8. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents.
Osada Y; Tsuchimoto M; Fukushima H; Takahashi K; Kondo S; Hasegawa M; Komoriya K
Eur J Pharmacol; 1993 Sep; 241(2-3):183-8. PubMed ID: 8243554
[TBL] [Abstract][Full Text] [Related]
9. [Inhibitors of xanthine oxidoreductase].
Okamoto K
Nihon Rinsho; 2008 Apr; 66(4):748-53. PubMed ID: 18409526
[TBL] [Abstract][Full Text] [Related]
10. Properties of xanthine dehydrogenase variants from rosy mutant strains of Drosophila melanogaster and their relevance to the enzyme's structure and mechanism.
Doyle WA; Burke JF; Chovnick A; Dutton FL; Whittle JR; Bray RC
Eur J Biochem; 1996 Aug; 239(3):782-95. PubMed ID: 8774727
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of xanthine oxidase and xanthine dehydrogenase by nitric oxide. Nitric oxide converts reduced xanthine-oxidizing enzymes into the desulfo-type inactive form.
Ichimori K; Fukahori M; Nakazawa H; Okamoto K; Nishino T
J Biol Chem; 1999 Mar; 274(12):7763-8. PubMed ID: 10075667
[TBL] [Abstract][Full Text] [Related]
12. Effect of TEI-6720, a xanthine oxidase inhibitor, on the nucleoside transport in the lung cancer cell line A549.
Yamamoto T; Moriwaki Y; Fujimura Y; Takahashi S; Tsutsumi Z; Tsutsui T; Higashino K; Hada T
Pharmacology; 2000 Jan; 60(1):34-40. PubMed ID: 10629441
[TBL] [Abstract][Full Text] [Related]
13. Substrate Orientation and Catalysis at the Molybdenum Site in Xanthine Oxidase: CRYSTAL STRUCTURES IN COMPLEX WITH XANTHINE AND LUMAZINE.
Pauff JM; Cao H; Hille R
J Biol Chem; 2009 Mar; 284(13):8760-7. PubMed ID: 19109252
[TBL] [Abstract][Full Text] [Related]
14. Crystal structures of urate bound form of xanthine oxidoreductase: substrate orientation and structure of the key reaction intermediate.
Okamoto K; Kawaguchi Y; Eger BT; Pai EF; Nishino T
J Am Chem Soc; 2010 Dec; 132(48):17080-3. PubMed ID: 21077683
[TBL] [Abstract][Full Text] [Related]
15. Xanthine dehydrogenase from Drosophila melanogaster: purification and properties of the wild-type enzyme and of a variant lacking iron-sulfur centers.
Hughes RK
Biochemistry; 1992 Mar; 31(12):3073-83. PubMed ID: 1313286
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and bioevaluation of 1-phenyl-pyrazole-4-carboxylic acid derivatives as potent xanthine oxidoreductase inhibitors.
Li J; Wu F; Liu X; Zou Y; Chen H; Li Z; Zhang L
Eur J Med Chem; 2017 Nov; 140():20-30. PubMed ID: 28918097
[TBL] [Abstract][Full Text] [Related]
17. The crystal structure of xanthine oxidoreductase during catalysis: implications for reaction mechanism and enzyme inhibition.
Okamoto K; Matsumoto K; Hille R; Eger BT; Pai EF; Nishino T
Proc Natl Acad Sci U S A; 2004 May; 101(21):7931-6. PubMed ID: 15148401
[TBL] [Abstract][Full Text] [Related]
18. Crystal structures of the active and alloxanthine-inhibited forms of xanthine dehydrogenase from Rhodobacter capsulatus.
Truglio JJ; Theis K; Leimkühler S; Rappa R; Rajagopalan KV; Kisker C
Structure; 2002 Jan; 10(1):115-25. PubMed ID: 11796116
[TBL] [Abstract][Full Text] [Related]
19. Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees.
Komoriya K; Osada Y; Hasegawa M; Horiuchi H; Kondo S; Couch RC; Griffin TB
Eur J Pharmacol; 1993 Dec; 250(3):455-60. PubMed ID: 8112406
[TBL] [Abstract][Full Text] [Related]
20. Reduction of nitrite to nitric oxide catalyzed by xanthine oxidoreductase.
Godber BL; Doel JJ; Sapkota GP; Blake DR; Stevens CR; Eisenthal R; Harrison R
J Biol Chem; 2000 Mar; 275(11):7757-63. PubMed ID: 10713088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
